Patients who are anti-gp210 positive at diagnosis exhibit markedly higher rates of hepatic failure (RR = 5.77, 95% CI: 2.9–11.48) and mortality (RR = 2.38, 95% CI: 1.62–3.51) [83]. The gene discussed is NUP210; the disease is liver failure.